Nymox Reports Encouraging Results From Long Term BPH Study
Posted on: Friday, 2 May 2008, 09:00 CDT
Nymox Pharmaceutical has announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia.
The study evaluated symptomatic progress of US patients involved in the company's two Phase I/II studies initiated in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 54 months after NX-1207 treatment. These subjects were last assessed at 42 months after treatment.
Overall, 75% of the patients in the new outcome study treated with NX-1207 reported no current drug treatment for their benign prostatic hyperplasia (BPH) and had a mean improvement of 11.1 points in AUA Symptom Score. In addition, 38% of the patients reported no other approved treatments at any time for their BPH since their original treatment with NX-1207, with a mean improvement of 9.8 points. This sustained improvement in BPH symptom score after NX-1207 treatment compares favorably to the 3.5 to five points reported in published studies of currently approved BPH drugs, which, unlike NX-1207 treatment, require uninterrupted, daily administration to be effective.
Paul Averback, CEO of Nymox, said: "This new data on NX-1207 showing sustained symptomatic improvement after 54 months provides further evidence of enduring benefits from NX-1207 treatment for BPH. NX-1207 thus far has had none of the well known sexual and other bothersome side effects of other BPH treatments."
Source: Datamonitor
Related Articles
- ICSI Plans Symposium on New Depression Treatment Program That Is Improving Patient Outcomes Five-Fold Over Typical Primary Care
- Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
- Jennerex Completes Treatment for First Patient Cohort in Phase I Cancer Study
- BioLineRx Completes Treatment of First Patient in Phase I/II Cardiac Study
- Nymox Reports Completion of New 42 Month Follow-Up Study of NX-1207 for BPH
- Axolotl's Community Wide Electronic Health Record Improves Patient Care in Western Colorado
- Vicriviroc Demonstrates Potent and Sustained Viral Suppression in ACTG Phase II Clinical Study in Treatment-Experienced HIV Patients
- FOSRENOL(R) Significantly Reduces Tablet Burden for End-Stage Renal Disease Patients With Hyperphosphatemia and Improves Patient and Physician Satisfaction, a New Study Reports
- Tenet Receives Grant From Robert Wood Johnson Foundation; 18-Month Project to Study Impact of Rapid Response Teams on Patient Safety
- New Planning Tool Streamlines Brachytherapy Treatments and Improves Patient Comfort
 |
 |
User Comments (0)
RSS Feeds